Unknown

Dataset Information

0

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.


ABSTRACT: Two dedicated receptors for bile acids (BAs) have been identified, the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, which represent attractive targets for the treatment of metabolic and chronic liver diseases. Previous work characterized 6?-ethyl-3?,7?-dihydroxy-5?-cholan-24-oic acid (INT-747), a potent and selective FXR agonist, as well as 6?-ethyl-23(S)-methyl-3?,7?,12?-trihydroxy-5?-cholan-24-oic acid (INT-777), a potent and selective TGR5 agonist. Here we characterize 6?-ethyl-3?,7?,23-trihydroxy-24-nor-5?-cholan-23-sulfate sodium salt (INT-767), a novel semisynthetic 23-sulfate derivative of INT-747. INT-767 is a potent agonist for both FXR (mean EC(50), 30 nM by PerkinElmer AlphaScreen assay) and TGR5 (mean EC(50), 630 nM by time resolved-fluorescence resonance energy transfer), the first compound described so far to potently and selectively activate both BA receptors. INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go-related gene potassium channel. In line with its dual activity, INT-767 induces FXR-dependent lipid uptake by adipocytes, with the beneficial effect of shuttling lipids from central hepatic to peripheral fat storage, and promotes TGR5-dependent glucagon-like peptide-1 secretion by enteroendocrine cells, a validated target in the treatment of type 2 diabetes. Moreover, INT-767 treatment markedly decreases cholesterol and triglyceride levels in diabetic db/db mice and in mice rendered diabetic by streptozotocin administration. Collectively, these preclinical results indicate that INT-767 is a safe and effective modulator of FXR and TGR5-dependent pathways, suggesting potential clinical applications in the treatment of liver and metabolic diseases.

SUBMITTER: Rizzo G 

PROVIDER: S-EPMC2981390 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.

Rizzo Giovanni G   Passeri Daniela D   De Franco Francesca F   Ciaccioli Gianmario G   Donadio Loredana L   Rizzo Giorgia G   Orlandi Stefano S   Sadeghpour Bahman B   Wang Xiaoxin X XX   Jiang Tao T   Levi Moshe M   Pruzanski Mark M   Adorini Luciano L  

Molecular pharmacology 20100714 4


Two dedicated receptors for bile acids (BAs) have been identified, the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, which represent attractive targets for the treatment of metabolic and chronic liver diseases. Previous work characterized 6α-ethyl-3α,7α-dihydroxy-5β-cholan-24-oic acid (INT-747), a potent and selective FXR agonist, as well as 6α-ethyl-23(S)-methyl-3α,7α,12α-trihydroxy-5β-cholan-24-oic acid (INT-777), a potent and selective TGR5 agoni  ...[more]

Similar Datasets

| S-EPMC5519354 | biostudies-literature
| S-EPMC6052932 | biostudies-literature
| S-EPMC5083223 | biostudies-literature
| S-EPMC8080777 | biostudies-literature
| S-EPMC6997404 | biostudies-literature
| S-EPMC2739652 | biostudies-literature
| S-EPMC4760777 | biostudies-other
| S-EPMC5684861 | biostudies-other
| S-EPMC7872982 | biostudies-literature
| S-EPMC3128138 | biostudies-literature